The goal of this observational study is to evaluate the local efficacy and safety of hydrodissection-assisted microwave ablation for patients with hepatocellular carcinoma, and to compare its therapeutic outcomes with surgical resection for hepatocellular carcinoma. The main questions it aims to answer are:
Is hydrodissection-assisted microwave ablation safe and effective for treating hepatocellular carcinoma? How does the therapeutic effect of hydrodissection-assisted microwave ablation compare with surgical resection for hepatocellular carcinoma? Patients who receive either microwave ablation or surgical resection will Undergo a 2-year follow-up period.
None
None
Patients diagnosed with hepatocellular carcinoma who underwent diaphragm hydrodissectionassisted microwave ablation or surgical resection at our hospital. All patients were definitively diagnosed with hepatocellular carcinoma based on combined imaging and pathological findings.
Cohort
Prospective
Microwave Ablation Assisted by Diaphragm Hydrodissection
Procedure/SurgeryFor subphrenic hepatocellular carcinoma treated with microwave ablation, ultrasound-guided injection of normal saline into the diaphragm is performed during ablation to establish a hydrodissection barrier and optimise lesion visualisation.
Surgical Resection
Procedure/SurgeryPatients with subphrenic hepatocellular carcinoma who undergo surgical resection are managed according to clinical diagnostic and therapeutic standards for hepatocellular carcinoma.
Progression-free survival (PFS)
the time from initiation of treatment to disease progression or death.
Overall survival (OS)
the time from initiation of treatment to death, loss to follow-up, or last follow-up.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
